User blogs
Nandrolone Phenylpropionate
Alias: Nandrolone Decanoate dosage
CAS No: 62-90-8
Einecs No: 200-551-9
MF: C27H34O3
MW: 406.56
Purity: 98%min
Appearance: White powder, special smell, dissolve in ethanol, slightly soluble in vegetable oil, almost insoluble in water.
Refrigeration save: Room temperature more than 20 Celsius degree to agglomerate, or so 30 Celsius degree into a liquid.
Product description
Libriol and Tribolan are trade names for Nandrolone Phenylpropionate,
another exotic anabolic preparation coming out of an Australian
company, RWR, which is shrouded in mystery. Anabolic NA is Syd Group's
entry into this bizarre combination of steroids. They all seem to be of
popular demand in bodybuilding circles primarily because of this
mystique. I will look at the pros and cons of this obscure drug,
Nandrolone Phenylpropionate, and if it qualifies to be in the muscle
building, fat-melting cycles of our future.
Libriol is an injectable
veterinary product containing short esters of the drugs nandrolone and
methandriol. Anabolic NA has the rare Nandrolone Cypionate, and Tribolan
contains the very long estered Nandrolone Decanoate. Steroid. COM
members should immediately recognize the first drug, nandrolone. A
steroid derived from modifying the testosterone molecule, Nandrolone is
one of the most popular drugs in the world and with good reason; It is a
versatile steroid that can be used in "bulking" or "cutting" cycles.
Applications:
Nandrolone Phenylpropionate (NPP) is the lesser known and less popular phenylpropionate ester version of nandrolone. First off its important to understand the difference between what we know as 'deca' and what we know as "NPP". To put it in simple terms the difference is simply the ester. NPP has the shorter ester while deca durabolin version of nandrolone has the longer 'deca' ester. Many lifters have no clue they can use the compound they love so much in a shorter ester. The only disadvantage would be the amount of injections, the shorter ester would have to be injected every other day or every 3 days at the most, while the long 'deca' ester can be injected once or twice a week. However the advantages are there which I will discuss as we go along.
To understand the other advantages of using Nandrolone
Phenylpropionate we must then understand half lives and what they mean.
To put it in simple terms NPP will be quicker to build up to peak levels
in the body and will be quicker once you stop injecting to filter out
of the body. Deca meanwhile because of the extremely long ester will
take much longer to build up and worst of all takes longer to trickle
out of the body, this will cause a much longer recovery for those of you
who cycle. So deca is a poor choice if you like to keep cycles under 10
weeks and want to run multiple cycles per year, and NPP is a realistic
option. Deca Durabolin will take about 6 weeks to clear out of your body
and is also detectable for up to 18 months! NPP meanwhile will clear
out much faster, I would guestimate about 2-3 weeks at the most where
the body can begin recovery. This 3-4 week difference is major when
dealing with nandrolones.
Another slight disadvantage with NPP is
some users will say the injections can be more painful then the much
smoother deca injection. However I can assure you it is nothing as bad
as prop.
Quick Detail:
Methenolone Acetate，Primo A (Primo E) dosage
Alias: Primobolan-depot: 1-methyl-3-oxoandrost-1-en-17-yl acetate; (5alpha, 17beta)-1-methyl-3-oxoandrost-1-en-17-yl acetate
Methenolone Acetate CAS No: 434-05-9
Methenolone Acetate Purity: 99%
Methenolone Acetate MF: C22H32O3
Methenolone Acetate MW: 344.49
Einecs No: 207-097-0
MOQ(minimum order quantity): 10gram
Standard: Enterprise Standard
Appearance: White powder.
Usage: It is very strong, the synthesis of the metabolism and male
characteristics is very low, making it the best choice for the game.
MOQ(minimum order quantity): 10gram
Standard: Enterprise Standard
Appearance: White powder.
Usage: Anabolic steroid. Androgen. Controlled substance.
Are you looking for something that can help in mass gaining in natural way?
Using anabolic steroids is the best way that help athletes and gym-goers or bodybuilders to make their muscles stronger and keep their stamina maintained. Testosterone Enanthate Powders are one of them that is an anabolic steroid counted as perfect for all levels of use.Buy Primo A (Primo E) powder in bulk
Being the perfect anabolic steroid for the first time steroid user and will be equally effective for the individual with a lot of time in the saddle, Testosterone Enanthate Powders is helpful in carrying with it possible side effects but we will also find they are very easy to control. If this is surprising it really shouldn’t be.
After all, although synthetic it’s simply testosterone, a hormone the human body is not only well-accustomed to but one that is essential to our health and wellbeing. There are a number of added benefits of using it. You have to choose the right dosage and place your order to consume.
Testosterone Enanthate Cycles and Uses
Testosterone Enanthate cycles are usually that of a bulking or mass gaining nature, though it can also be utilized in a very specific manner in cutting or fat loss cycles. For mass gaining or bulking, Testosterone Enanthate is usually employed in a higher dosage (usually a minimum of 500mg per week), and because it is an anabolic steroid with a long ester affixed to it, it will exhibit a longer half-life of around 7 – 10 days, and therefore Testosterone Enanthate cycles are usually run for periods of 10 – 12 weeks or longer.
In both bulking and cutting cycles, Testosterone Enanthate is commonly stacked with other compounds of a nature that will facilitate the user’s end goal (bulking, mass gaining, or fat loss). For example, Testosterone Enanthate cycles for the purpose of bulking usually include the use of Deca-Durabolin (Nandrolone Decanoate) and/or Dianabol (Methandrostenolone), where Dianabol is usually run for the first 6 weeks as a kick-starting compound.
in case of Testosterone Enanthate cycles are cutting or fat loss cycles, Testosterone Enanthate is usually run at a very low TRT (Testosterone Replacement Therapy) dosage of around 100mg per week whilst other compounds more preferable for cutting and fat loss are emphasized during the cycle.
Buy Testosterone Enanthate Powder
In order to buy Testosterone Enanthate powder, what all you have to do is search for the right store or reach a reliable supplier. Online search will help you in finding the right supplier. SteroidsFather is a trusted online store offering you Testosterone Enathate Powder with a user guide and information about the potential complications and benefits too.
Prices are competitive and backed by attractive discounts; while you can place your order from anywhere and anytime and get them delivered in safe and secure way to your address.
Testosterone Enanthate is an anabolic steroid that is perfect for all levels of use. This is the perfect anabolic steroid for the first time steroid user and will be equally effective for the individual with a lot of time in the saddle. It will carry with it possible side effects but we will also find they are very easy to control. If this is surprising it really shouldn’t be. After all, although synthetic it’s simply testosterone, a hormone the human body is not only well-accustomed to but one that is essential to our health and wellbeing.
Testosterone Enanthate Cycles and Uses
Testosterone Enanthate cycles are usually that of a bulking or mass gaining nature, though it can also be utilized in a very specific manner in cutting or fat loss cycles. For mass gaining or bulking, Testosterone Enanthate is usually employed in a higher dosage (usually a minimum of 500mg per week), and because it is an anabolic steroid with a long ester affixed to it, it will exhibit a longer half-life of around 7 – 10 days, and therefore Testosterone Enanthate cycles are usually run for periods of 10 – 12 weeks or longer.
In both bulking and cutting cycles, Testosterone Enanthate is commonly stacked with other compounds of a nature that will facilitate the user’s end goal (bulking, mass gaining, or fat loss). For example, Testosterone Enanthate cycles for the purpose of bulking usually include the use of Deca-Durabolin (Nandrolone Decanoate) and/or Dianabol (Methandrostenolone), where Dianabol is usually run for the first 6 weeks as a kick-starting compound.
In the event that Testosterone Enanthate cycles are cutting or fat loss cycles, Testosterone Enanthate is usually run at a very low TRT (Testosterone Replacement Therapy) dosage of around 100mg per week whilst other compounds more preferable for cutting and fat loss are emphasized during the cycle.
Because Tren is 19, and he does not carry the risk of increasing prolactin, which prevents you from going out during sex. This is what prevents you from getting an erection in the first place (tren dick), and this is what gives you breast tissue. Some people will tell you that it's impossible to get a bitch from tren, it's completely wrong, in fact it's a very common side, like most anabolics.
To combat this, you can add to your cycle Dostinex (generic name Caber) or Pramipexole (aka Pramie). Or click here to learn how to prevent Gyno naturally.
Dostinex is good, but it's hard to get, and this hell is much more expensive, it also comes with its own side effects.
If you can not find Dostinex, then Gynectrol is the next best thing. These are natural ingredients, so it's much safer, easier to find and much cheaper. Read more here.
There's also a new answer to fighting cardiovascular problems with Tren, if you can get it, and it's called GW-501516.
By adding the GW-510516 to your cycle, you can counteract negative cardiovascular sides and allow yourself to perform both aerobic and anaerobic cardiovascular exercises in the usual mode.
GW-501516 was banned by WADA (the World Anti-Doping Association) because of the significant advantage it gives to athletes participating in endurance competitions. It normalizes blood pressure, reduces cholesterol and heart rate to a safer level and allows you to improve your health and improve your health.
The optimal dosage of GW-501516 is 20 mg per day, which is good for a period of up to 12 weeks before a 4-week rest period is required. After a rest period, you can restart it.
Not very good news (again!) - even with the above, there are still significant risks with the use of Trenbolone, and you should be aware of them.
Victoza falls under the umbrella of incretin mimetics, a class of drugs used to treat type 2 diabetes that works by boosting insulin production in the pancreas, lowering the patient’s blood sugar levels.Liraglutide powder
Victoza, which is manufactured by Novo Nordisk, was first approved for market in 2010. It quickly became one of the most popular type-2 diabetes treatments.
However, more recently Victoza has faced criticisms over its dangerous side effects, which Novo Nordisk failed to warn consumers about. As a result, a number of Victoza lawsuits have been filed against the manufacturer on behalf of individuals who were injured by Victoza.Byetta (exenatide) is a GLP-1 receptor agonist which mimics the effect of glucagon-like peptide-1, a hormone that increases insulin production when blood sugar is high. Byetta is administered as a twice-daily injection.
Bydureon is also a GLP-1 receptor agonists and contains the same main ingredient as Byetta – exenatide. Bydureon is a longer-lasting version of Byetta, requiring a once a week injection.
Rather than an injection, Januvia (sitagliptin) is a once-daily pill
used to lower blood glucose levels in patients with Type 2 diabetes.
Januvia helps to increase the insulin produced by the pancreas when
blood sugar levels are high and help to reduce the amount of sugar
produced by the liver. Also a pill, Janumet is a combination drug – it
combines sitagliptin and metformin into a single pill.
Researchers
have linked Victoza to a number of dangerous and potentially
life-threatening side effects. These side effects were not included on
the original Victoza warning label and the public has now been made
aware of these side effects by researchers and through drug safety
communications.
Pancreatitis and Pancreatic Cancer — Following a number of concerning
reports linking Victoza to pancreatitis, the U.S. Food and Drug
Administration (FDA) conducted an investigation into Victoza health
risks in 2013. The FDA found that pancreatitis was more likely to occur
in patients using Victoza than in patients using any other type-2
diabetes medication. As a result, the FDA mandated a black box warning
making consumers aware of Victoza’s increased risk of pancreatitis.
Other research and studies have shown that this form of type-2 diabetic
treatment may be linked to pancreatic cancer. In a recent clinical
trial, 13 patients were diagnosed with pancreatic cancer while only 5
patients taking the placebo were diagnosed with pancreatic cancer.
Thyroid Cancer — Following a number of concerning reports linking
Victoza to thyroid cancer, the U.S. Food and Drug Administration (FDA)
mandated a black box warning for the drug, the strongest warning a drug
can carry. Researchers found an increased risk of tumors — sometimes
cancerous — developing in the thyroid glands of rats and mice.
If
you are taking Victoza and have developed pancreatic cancer,
pancreatitis, or thyroid cancer, you should stop taking Victoza and talk
to your doctor and an experienced personal injury lawyer right away.
If you had previously taken Victoza and have developed pancreatic cancer, pancreatitis, or thyroid cancer, you should contact an experienced personal injury lawyer right away.
Novo Nordisk has secured approval for Liraglutide powder (liraglutide) from the US Food and Drug Administration (FDA) to treat paediatric patients aged ten years or older with type 2 diabetes.
Victoza is claimed to be the first non-insulin drug approved to treat the condition in paediatric patients. It has been used for adult patients since 2010.
Acting director at the FDA Center for Drug Evaluation and Research’s Division of Metabolism and Endocrinology Products (DMEP) Lisa Yanoff said: “Victoza has now been shown to improve blood sugar control in paediatric patients with type 2 diabetes.
“The expanded indication provides an additional treatment option at a time when an increasing number of children are being diagnosed with this disease.”When administered, Victoza works by creating the same effects in the body as the glucagon-like peptide (GLP-1) receptor protein in the pancreas and improves blood sugar levels.
Victoza slows digestion, prevents the liver from making too much glucose, and helps the pancreas produce more insulin when needed.
It can also be used to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes and established CV disease.
Novo Nordisk carried out several placebo-controlled trials in adults and one placebo-controlled trial with 134 pediatric patients to evaluate the efficacy and safety of Victoza for reducing blood sugar in patients with type 2 diabetes.
The drug is not a substitute for insulin and is not indicated for patients with type 1 diabetes or those with diabetic ketoacidosis. No clinical trials were conducted to study the effect of the drug on major adverse CV events in paediatrics.
LISBON – The investigational glucagon-like peptide (GLP)-1 receptor agonist semaglutide added to standard care for type 2 diabetes mellitus (T2DM) resulted in clinically significant weight loss over 2 years in the SUSTAIN-6 phase 3 trial.
Participants treated with semaglutide in the study lost an average of
3.6 to 4.9 kg, depending on the dose they were given (0.5 mg or 1.0
mg), which was significantly (P less than .0001) more than those who
were randomized to matching placebos (-0.7 mg and -0.5 mg).“A
dose-response effect was observed on weight loss with semaglutide
treatment,” study investigator Agostino Consoli, MD, reported at the
annual meeting of the European Association for the Study of Diabetes.
Semaglutide is under development by Novo Nordisk and is currently under
review by regulatory agencies in the United States, Europe, and Japan.
It has 94% homology to human GLP-1 and modifications have been made to
help it avoid degradation and which give it a half-life that allows it
to be given once a week.
SUSTAIN 6 is part of an ongoing phase 3
program and is a long-term outcome study with the primary objective of
evaluating the cardiovascular safety of semaglutide. Effects on macro-
and microvascular complications, glycemic control, body weight, body
mass index and weight circumference are key secondary endpoints,
together with assessment of its overall safety and tolerability.GHRP-2 powder,GHRP 2 powder
Other trials in the program, have evaluated treatment with semaglutide
as monotherapy (SUSTAIN 1; Lancet Diabetes Endocrinol. 2017;5:251-60) or
versus other treatments including sitagliptin (Januvia, Merck; SUSTAIN
2; Lancet Diabetes Endocrinol. 2017;5:341-54), exenatide extended
release (Bydureon, AstraZeneca; SUSTAIN 3), or insulin glargine (SUSTAIN
4), as add-on to basal insulin with or without metformin (SUSTAIN 5),
and most recently, versus dulaglutide (Trulicity, Eli Lilly; SUSTAIN 7).
SUSTAIN 6 involved 3,297 people with T2DM with established cardiovascular disease or chronic kidney disease or otherwise identified as being at increased cardiovascular risk, according to Dr. Consoli, who is an endocrinologist and professor at the University of Chieti-Pescara, Italy. The results of the primary endpoint have been reported (N Engl J Med. 2016; 375:1834-44) and showed that the composite rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo. The hazard ratio for the reduction in the composite endpoint was 0.74 (95% CI, 0.58-.95; P less than .001 for noninferiority).
Results of the secondary analyses reported by Dr. Consoli at EASD 2017 showed that semaglutide could help more patients than placebo achieve significant weight loss, which could help further reduce their cardiovascular risk. He reported that a 5% or greater weight loss at 2 years was achieved by 36% and 47% of patients treated with semaglutide 0.5 mg and 1 mg groups, respectively, and by 18% and 19% of patients in the matching placebo groups (P less than .0001 for both comparisons). A 10% or greater weight loss was achieved by 13% and 21% of the semaglutide-treated patients and by 6% and 7% of those given placebo.
“The effect of weight was not dependent on BMI [body mass index] at baseline,” Dr. Consoli said, emphasizing that there was a consistent reduction in the weight in all BMI categories. Importantly, Dr. Consoli observed, the effects of semaglutide on weight seen were not driven by just a few patients losing weight, and around 80% of patients in the study experienced some degree of weight loss.
“As expected, the subjects treated with the GLP-1a had more GI [gastrointestinal] effects,” Dr. Consoli reported. Nausea or vomiting were reported in twice as many patients treated with semaglutide 0.5 mg (21.9%) and 1 mg (27.3%) as their placebo-matched counterparts (10.8% and 10.6%).
A post-hoc analysis found that the effect of semaglutide on weight loss was not likely to be down to these side effects, however, with a similar weight reductions seen in those who did and did not experience nausea or vomiting. The “estimated natural direct effect of treatment” was -2.75 kg for the 0.5 mg dose and -4.32 for the 1 mg dose of semaglutide versus their placebos Dr. Consoli said. GI drove the weigjht loss to a small degree; -0.12 kg and -0.04 kg of weight loss seen in the 0.5 mg and 1 mg semaglutide groups versus their placebos could be ascribed to nausea or vomiting.
In a poster presentation at the meeting, data on another post-hoc analysis from the SUSTAIN phase 3 program were reported. In a responder analysis of T2DM patients achieving glycemic and weight loss thresholds, a greater proportion of those treated with semaglutide achieved clinically meaningful reductions in both glycated hemoglobin (HbA1c) and body weight than those given comparator treatments.
The composite endpoint of at least a 1% reduction in HbA1c and a 5% or greater decrease in body weight was achieved by 25%–35% of patients treated with the 0.5 mg dose of semaglutide, by 38%–56% of those given the higher dose, and by 2%–13% or all comparators (P less than .0001). The higher dose of semaglutide also allowed more people to achieve this endpoint than the lower dose.
Novo Nordisk supported the study. Dr. Consoli disclosed receiving research funding from AstraZeneca and Novo Nordisk and speaker’s bureau or consultation fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Merck, Sharp & Dohme, Novartis, Sanofi-Aventis, and Takeda.
Last week, Theratechnologies Inc. began marketing a new medicine called tesamorelin (Egrifta)—licensed for the treatment of excess belly fat in some HIV-positive people. Tesamorelin powder causes the body to produce growth hormone and, as a result, most tesamorelin users can lose some degree of belly fat.
Summary
Tesamorelin is a small molecule that stimulates the brain to produce growth hormone. This hormone helps to reduce the amount of fat in the belly of some HIV-positive people. Tesamorelin does not affect the fatty layer just under the skin (subcutaneous fat) in the face or other parts of the body. Prior to prescribing tesamorelin, Health Canada requires physicians to request a CT scan of a patient’s abdomen to confirm the presence of excess belly fat. Tesamorelin is injected under the skin once daily. In clinical trials, participants who had previously lost belly fat while taking tesamorelin had belly fat return when they stopped taking the drug. In Canada, tesamorelin is expected to cost about $3,000 per patient per month.
Some notes on belly fat, growth hormone and HIV
The fat that accumulates within the belly is called visceral fat. In general, among adults, as the amount of belly fat increases, production of growth hormone decreases. Studies from the 1980s and early-to-mid-1990s suggested that some HIV-positive adults produced lower-than-ideal levels of growth hormone. This reduced production of growth hormone led to changes in the composition of the body—an accumulation of belly fat and a loss of some lean tissue (muscle).
About tesamorelin
Tesamorelin is a small molecule (called a peptide). This drug stimulates a gland in the brain, called the pituitary gland, to release growth hormone. Increased production of growth hormone can cause excess belly fat to diminish.
Clinical trials with HIV-positive people
Tesamorelin has been tested in more than 800 HIV-positive people in well-designed clinical trials. Many participants used tesamorelin for between six and 12 months. This usually resulted in a significant decrease in belly fat compared to placebo (fake tesamorelin). There was a small increase in muscle mass among tesamorelin users and no loss of subcutaneous fat. Levels of triglycerides, a fatty substance in the blood, decreased modestly among tesamorelin users.
When participants who had previously received tesamorelin were instead given placebo, all of the beneficial effects of tesamorelin disappeared.
The hormone insulin is used to help regulate blood sugar levels. After initiating therapy with tesamorelin, the body’s ability to respond to insulin may change. During clinical trials, participants who received tesamorelin were more likely to develop elevated levels of blood sugar because their bodies became less sensitive to the effects of insulin. However, among participants who took tesamorelin for up to one year, problems with blood sugar levels generally resolved.
Verified Market Research represents the Gonadorelin Market 2026. Detail analysis of the parent market based on Key players, present, past and artistic movement information which is able to offer as a profitable guide for all Gonadorelin Market competitors. The analysis Advanced Gonadorelin Market covers an overview of the industry policies that Gonadorelin Market considerably, the price structure of the product obtainable in the market, and their producing chain. Gonadorelin business report is helpful for future strategy development, and to know about Market Drivers, Restraints, Opportunities, and Global Market Size, Share, Growth, Trends, Key players forecast to 2026.Gonadorelin Acetate powder,Gonadorelin powder
The study provides detailed information on the established
Gonadorelin Market with a strong perceptive of world market players and
emerging market associations through market research reports. This also
includes producing Analysis, Size, Share, Supply, Demand, CAGR, Forecast
Trends, Sales, Production, and Business Trends.
The report covers a
detailed analysis of growth factors, constraints, opportunities, and
challenges Gonadorelin Market. It additionally includes extensive
analysis on the latest trends in the market to determine Gonadorelin
Market growth. The report aims to produce an overview of world
Gonadorelin market with careful market segmentation. Also, it analyses
this Gonadorelin market situation and forecasts the market until 2026.
The report covers market dynamics affecting the market throughout the
forecast period. What is more, the report analyses the competitive
scenario, geographic trends, and opportunities within the markets with
regard to all geographic regions. The report conjointly includes the
elaborated company profiles of the key players within the market beside
their market methods.
Delays in rebreeding can be costly. Synchronization programs with producer- and veterinarian-trusted products from Zoetis result in more efficient breeding, saving time and protecting your bottom line. FACTREL® Injection (gonadorelin injection) has an FDA-approved label to be used in conjunction with LUTALYSE® Injection (dinoprost injection) to synchronize estrous cycles to allow for fixed-time artificial insemination (FTAI) in lactating dairy cattle.Gonadorelin Acetate powder,Gonadorelin powder
FACTREL is now available in a larger, more convenient 50-mL bottle. Now you can treat up to 25 cows per bottle of FACTREL compared with just 10 doses in the 20-mL bottle. With more than 12,000 total cows studied, you can have confidence that FACTREL is effective. Now you can adapt a reproduction program that fits your management needs, with flexible schedule and dosing with FACTREL and LUTALYSE.
FACTREL is also indicated for the treatment of ovarian follicular cysts in cattle. When used in cattle with ovarian follicular cysts, treatment effect is to reduce the number of days to next estrus.
It’s more than just the bottle. Zoetis works with you to make appropriate decisions about the use of LUTALYSE and FACTREL in your herds and to create a comprehensive approach for your reproduction program, so you can set and achieve higher pregnancy rate goals, improving your milk production and increasing the opportunities you have for herd improvement through genetic selection.